ATOR-1015 is a tumor-directed CTLA-4 antibody that targets the CTLA-4 and OX40 receptors, designed to work in combination with PD-1/PD-L1 therapies.
“We have worked previously with the Theradex London office on the ADC-1013 clinical phase I trial and were very pleased with their extensive expertise and high-quality delivery,” said spokesperson Cecilia Hofvander.
“We are looking forward to a likewise successful collaboration on ATOR-1015,” she added.
The trials – expected to begin in the second half of this year – will take place across five sites in Sweden and Denmark.
Hofvander said the immune activating effect of ATOR-1015 – directed towards the tumor since both targets CTLA-4 and OX40 are upregulated in the tumor microenvironment – could strongly reduce immune-related adverse effects.
Further, “CTLA-4 is the only target that has shown clinical synergy with PD-1 to date, but this combination is unfortunately severely hampered by toxicity.
“We believe that ATOR-1015 can add CTLA-4 efficacy with far less toxicity, which would allow for combination with PD-1 therapy in a much larger population,” she said.
Alligator said it does not anticipate any particular challenges, beyond those of a typical immuno-oncology clinical trial.
“Recruitment is always a critical factor, but we have very good experience of recruitment from our clinical sites using similar inclusion and exclusion criteria and are confident that this will be managed successfully,” Hofvander told us.